News | 09 June 2026
Bayer brings Alka-Seltzer to India touting first antacid with probiotic support
The launch comes against the backdrop of a significant public health burden
The launch comes against the backdrop of a significant public health burden
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Veteran pharma and biotech executive brings over 20 years of commercial leadership experience to support LMS's global CDMO and API growth strategy
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The newly commissioned facility strengthens the ’company’s capabilities in the development and manufacturing of generic and complex sterile injectable products
The greenfield facility in Madhya Pradesh expected to create up to 500 direct jobs, in addition to generating indirect employment opportunities
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Exclusive partnership to expand access to high-quality seamless anodized aluminium packaging for sterile APIs and pharmaceutical products across India.
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The company recycled approximately 100 kilograms of textile waste, undertook plantation activities, and encouraged employees to adopt environmentally responsible practices
Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
The move signals a major expansion in access to next-generation weight-loss therapies
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
